Related Experiment Video
Updated: Aug 4, 2026

Treatment of Platelet Products with Riboflavin and UV Light: Effectiveness Against High Titer Bacterial Contamination
Published on: August 24, 2015
Bactericidal capacity of platelets in gastric cancer patients
Z Kamocki1, J Matowicka-Karna, Z Piotrowski
1II Department of General and Gastroenterological Surgery, Medical University of Bialystok, 15-276, Poland. zkamocki@yahoo.com
Abstract:
The aim of this study was to evaluate bactericidal capacity of platelets in patients suffering from gastric cancer. Number of platelets and their bactericidal activity were measured in 32 cancer patients (divided into 2 groups: I--resectable cancer, II--non-resectable one) and 32 normal donors. In group I the number of platelets was 259.136+/-84.459 x 103/microl. It was increased comparing to the normal donors 193.219+/-55.493 x 103/microl. After the surgery increase in platelet number was observed (472.05+/-111.772 x 103/microl). In group II an increased number of platelets was observed (265.1+/-81.813 x 103/microl) and it was maintained in a post-operative period: 234.2+/-54.141 x 103/microl. In group I bactericidal capacity of platelets was 2.25+/-7.33%, whereas it increased significantly after the surgery--4.7+/-7.46%. In group II, it was 8.6+/-17.61% before and 4.72+/-4.76% after the surgery. In normal donors this ability was 21.66+/-16.66. In gastric cancer patients increased platelet number was observed. Significant increase in platelets number occurred after a radical tumor removal. Decreased bactericidal activity of platelets was noticed in gastric cancer patients. After surgical removal of the tumor, platelets partly reclaimed bactericidal capacity. In patients presenting disseminated gastric cancer, bactericidal capacity of platelets could be permanently impaired.
Related Concept Videos
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Peptic Ulcer
Gastritis II: Pathophysiology

